VivoSeq
Oncology

Locally Advanced or Metastatic Solid Tumors

4

Pipeline Programs↗

55

Active Trials↗

47

Companies Involved↗

Locally Advanced or Metastatic Solid Tumors is an early-stage landscape with 4 programs across 47 companies. The most active players are Roche, Merck & Co., Innovent Biologics (Suzhou) Co. Ltd..

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

37/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

PreclinicalS

Sichuan Baili Pharmaceutical Co., Ltd.

0 programs

PreclinicalA

Avistone Biotechnology Co., Ltd.

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 14

XB010

Exelixis

Pembrolizumab

Merck & Co.

Enzelkitug

Roche

Atezolizumab

Roche

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

152

clinical trials

Completed67 · 44%
Recruiting38 · 25%
Terminated17 · 11%
Active, not recruiting10 · 7%
Unknown status8 · 5%
Not yet recruiting7 · 5%
Other5 · 3%

Clinical Trials

Trial Activity

152 trials

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Recruiting·AAadi Bioscience, Inc.·Phase 1·NCT05661461·28 enrolled
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting·VVir Biotechnology, Inc.·Phase 1·NCT06960395·450 enrolled
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting·AAvistone Biotechnology Co., Ltd.·Phase 1·NCT06307795·63 enrolled
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting·EExelixis·Phase 1·NCT07123103·150 enrolled
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT06349408·250 enrolled
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT06418061·198 enrolled
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Recruiting·PPlexium, Inc.·Phase 1·NCT07284186·155 enrolled
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
Recruiting·AABL Bio, Inc.·Phase 1·NCT04762641·100 enrolled
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06718621·22 enrolled
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1·NCT06046742·12 enrolled
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting·Day One Biopharmaceuticals logoDay One Biopharmaceuticals·Phase 1·NCT06752681·254 enrolled
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting·AAvistone Biotechnology Co., Ltd.·Phase 1·NCT06716138·96 enrolled
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04879121·13 enrolled
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06349811·30 enrolled
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT06172478·740 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)